Articles related to RESEARCH & CLINICAL TRIALS

Sanbexin’s sublingual formulation offers a potential paradigm shift in acute ischemic stroke treatment, enabling flexible administration outside traditional hospital settings.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

The STRIDE regimen demonstrated a 30.7% survival rate at 36 months, compared to 20.2% with sorafenib, suggesting potential long-term benefits for patients with unresectable hepatocellular carcinoma.

Adjuvant durvalumab therapy led to a median overall survival of 55.9 months compared to 33.4 months with placebo in patients with limited-stage small-cell lung cancer who did not progress after chemoradiotherapy.

A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.

Recent studies suggest that ALS may begin to develop shortly after conception, taking years or decades before symptoms appear, highlighting the importance of early intervention and lifestyle modifications.